High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
8.31am: AstraZeneca talks suggest 'reduced confidence' in outlook AstraZeneca's reported talks with Bristol Myers about creating a $400 billion company appear to make "limited strategic sense for Astra and would likely be subject to antitrust scrutiny, given the overlaps of their oncology...
Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.
The Morning Bull - US Market Morning Update Monday, Jul, 20 2026 US stock futures are pointing lower this morning, with E mini S&P 500 contracts down around 1%, as investors weigh falling bond yields against a cooling housing backdrop. The US 10 year Treasury yield has slipped to about 4.5% after softer inflation readings. In plain terms, this means borrowing costs in financial markets are easing a little even as the debate over the Federal Reserve's next move continues. At the same time,...
The robot-assisted surgery pioneer's growth could be decelerating.
Shares of the Maker of Robotic Surgical Tools Led S&P 500 Decliners on Friday
Revenue rose 19% and procedures grew 16%, but held guidance
ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
Revenue rose 19% and procedures grew 16%, but held guidance
All three major US stock indexes were down Friday, as chipmakers led the way down on the final tradi
According to TheFly, Citi lowered its price target to $500 from $590 and keeps a ‘Buy’ rating.
Investing.com - U.S. stock index futures fell sharply on Friday, pointing to a second straight day of losses on Wall Street as investors continued to reassess lofty technology valuations following a string of disappointing corporate updates tied to artificial intelligence spending.
Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.
Ahead of the bell Wall Street looks set to be headed for the red with US stock futures falling on Friday, leaving the major indices on course for weekly losses as the semiconductor sell-off rolled on. Dow Jones futures slipped 0.6%, and S&P 500 contracts dropped around...
Intuitive Surgical (ISRG) shares fell early Friday as growth in the company's da Vinci robotic surge
Intuitive Surgical issued lackluster procedure guidance for the year on Thursday, leading the stock to take a dive.
Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 18.5% year on year to $2.89 billion. Its non-GAAP profit of $2.80 per share was 11.9% above analysts’ consensus estimates. Stock drop is primarily driven by recent declines in overall surgery volumes, which were reported by major healthcare providers, as well as a recent Class II recall of certain da Vinci surgical components.
In April 2026, Intuitive Surgical voluntarily initiated an ongoing Class II worldwide recall of certain da Vinci surgical system components after discovering an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers. This safety action, alongside growing attention on Intuitive’s AI-enabled da Vinci 5 rollout and competitive pressures in robotic surgery, raises fresh questions about how...
Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.
Intuitive Surgical (ISRG) is in focus after voluntarily recalling certain Da Vinci surgical system components tied to a potential E-brake pin issue. This development is prompting fresh attention on product risk and how it might factor into the stock. See our latest analysis for Intuitive Surgical. Against this backdrop, Intuitive Surgical’s short term share price momentum has softened, with the stock down 4.5% over the past week and 9.7% over the past 90 days. However, the 3 year total...
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the top high-conviction stocks to buy according to hedge funds. Deutsche Bank cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 on June 2 while maintaining a Sell rating on the shares. The stock also received a rating update from BofA on May 12, […]
While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.
Due to Baxter International's underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
While Align Technology has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.
Intuitive Surgical falls 11% in a month despite strong revenues, procedure growth and da Vinci 5 adoption, raising questions about a potential rebound.
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.
Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
